Drug-Induced Anaphylactic Shock

Among the major etiological factors that can cause an anaphylactic shock (AS), drugs account for 31.2-46.5%.

Purpose of the work was to identify factors associated with a high AS risk based on 2010-2018 records made in the Republic of Crimea.

Materials and methods. The objects of the study were 112 information reports about adverse reactions (AR) to medicine remedies (MR), which were recorded in the regional database of spontaneous information reports—ARCAD — in the Republic of Crimea during 2010-2018. A retrospective analysis of drug-induced AS cases has been carried out for the following indicators: intake and route of administration of drugs, gender, age, history of allergies.

Results of the study have shown that antimicrobial drugs, local anesthetics, analgesics-antipyretics, X-ray contrast iodine-containing substances, and non-steroidal anti-inflammatory drugs featured the highest AS incidence. Most frequently, AS cases were observed in patients aged 31 to 60 years, with no significant differences between men (57 cases) and women (54 cases). In one case the patient's gender was missed or not stated.

The leader in AS incidence is Ceftriaxone, which application was associated with 22 cases of such AR. In 87 cases, AS was found associated with parenteral administration drugs, the intravenous route of administration being predominant (44 cases). In 97 cases, development of drug-induced AS was life-threatening and required emergency pharmacotherapy; 8 reports contained a lethal outcome record.

Conclusions. Attention should be paid to high incidence, severity, and instant progression rate of adverse reactions in the form of AS. Considering the AS progression rate and facts of ignored past history of drugs and allergies, as well as pharmacological correction errors, additional educational events are worth conducting for physicians specializing in different fields.

1. Powrie R.O. Anaphylactic shock in pregnancy. Critical care obstetrics. 2018; chapter 40: 641-665. DOI: 10.1002/9781119129400.ch40.

2. Pawankar R., Holgate S.T., Canonica G.W., Lockey R.F., Blaiss M.S. World Allergy Organization. White Book on Allergy: Update 2013. 2013: 242 p. ISBN-10: 0615929168.

3. Novikov D.K., Vyxristenko L.R., Novikov P.D., Titova N.D., Ishhenko O.V., Semenova I.V., Yanchenko V.V. Anaphylaxis. Anaphylactic shock. The clinical picture, diagnosis, treatment: allowance. D. Vitebsk: Voronezh State Medical University, 2018. 103 p [In Russ.].

4. Anaphylactic shock. Clinical recommendations. Ministry of Health of the Russian Federation. Moscow, 2016: 36 p [In Russ.].

5. Wood R.A., Camargo C.A., Lieberman P., Sampson H.A., Schwartz L.B., Zitt M., Collins C., Tringale M., Wilkinson M., Boyle J., Simons F.E. Anaphylaxis in America: The prevalence and characteristics of anaphylaxis in the United States. J. Allergy Clin. Immunol. 2014; 133: 461-467. DOI: 10.1016/j.jaci.2013.08.016.

6. Turner J.P, Gowland H.M., Sharma V, Ierodiakonou D., Harper N., Garcez T., Pumphrey R., Boyle R.J. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: An analysis of United Kingdom national anaphylaxis data, 1992- 2012. J. Allergy Clin. Immunol. 2015; 135: 956-963. DOI: 10.1016/j.jaci.2014.10.021.

7. Ye Y., Kim M., Kang H., Kim T., Sohn S., Koh Y., Park H.K., Jang G.C., Kim C.W., JeeY.K., HurG.Y., KimJ.H., Kim S.H., Choi G.S., LeeS.K., Park H.S. Predictors of the Severity and Serious Outcomes of Anaphylaxis in Korean Adults: A Multicenter Retrospective Case Study. Allergy Asthma Immunol. 2015; 7 (1): 22-29. DOI: 10.4168/aair.2015.7.1.22.

8. JerschowE., LinR.Y., ScaperottiM.M., McGinnA.P. Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations. J Allergy Clin Immunol. 2014; 134 (6): 1318-1328.e7. DOI: 10.1016/j.jaci.2014.08.018.

9. Campbell R.L., Hagan J.B., Manivannan V, Decker W.W., Kanthala A.R., Bellolio M.F., Smith V.D., Li J.T. Evaluation of national institute of allergy and infectious diseases/food allergy and anaphylaxis network criteria for the diagnosis of anaphylaxis in emergency department patients. J Allergy Clin Immunol. 2012; 29 (3): 748-52. DOI: 10.1016/j.jaci.2011.09.030.

10. ATC/DDD Index 2019. Available at: https://www.whocc.no/atc_ddd_index/

11. Federal Law FL No. 61 dated April 12, 2010 «Circulation of Medicine». Available at: http://www.consultant.ru/document/cons_doc_LAW_99350/ [In Russ.]

12. Ring J., Franz R., Brockow K. Anaphylactic reactions to local anesthetics. Chem Immunol Allergy. 2010; 95: 190-200. DOI: 10.1159/000315952.

13. Nakamura N., Tamagava-Mineoka R., Masuda K., Katoh N. Immediate-type allergic reactions to local anesthetics. Allergology International. 2018: 67 (1): 160-161. DOI: 10.1016/j.alit.2017.07.003.

14. AkhmedzyanovaD.G.,RakhmatullinaN.M., SibgatullinaN.A., Delyan V.U., Zakirova G.N., Trofimova O.R., Panteleymonova P.M. Acute adverse reactions for contrast medium infi ltration in medical practice. Vestnik sovremennoj klinicheskoj meditsiny. 2018; 11 (5): 100-104 [In Russ.]. DOI: 10.20969/VSKM.2018.11 (5).100-104.

15. Russian Association of Allergologists and Clinical Immunologists: Federal Clinical Recommendations for Anaphylactic Shock. Approved by the RAACI Presidium on December 23, 2013. Available at: http://www.raaci.ru/ClinRec/8.Anaphylaxy.pdf [In Russ.]

16. Glotov M.A., Znamenskaya L.K., Konyaeva E.I. Clinical protocol for the prevention and treatment of anaphylaxis. Simferopol, 2016. 24 p [In Russ.].

17. JaresE. J., Baena-Cagnani C.E., Sanchez-BognesM., EnsinaL.F., Arias-Cruz A. Drug-induced anaphylaxis in Latin American countries. The Journal of Allergy and Clinical Immunology: in Practice. 2015; 3 (5): 780-788. DOI: 10.1016/j.jaip.2015.05.012.

18. Lee S.Y., Ahn K., Kim J., Jang G.C., Min T.K., Yang H.J. A multicenter retrospective case study of anaphylaxis triggers by age in Korean children. Allergy, asthma & immunology research. 2016; 8 (6): 535-540. DOI: 10.4168/aair.2016.8.6.535.

19. Matveev A.V., Krasheninnikov А.Е., Egorova Е.А., Konyaeva E.I. Investigation of medically induced skin reactions based on the analysis of reports of adverse drug reactions in the Republic of Crimea (from 2009 to 2016). Farmatsiya i farmakologiya (Pharmacy & Pharmacology). 2019; 7 (1): 32-41 [In Russ.]. DOI: 10.19163/2307-9266-2019-7-1-32-41.